Aethlon Medical Inc.
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
IPO Year:
Exchange: NASDAQ
Website: aethlonmedical.com
Recent Analyst Ratings for Aethlon Medical Inc.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/25/2021 | $5.00 → $9.00 | Buy | HC Wainwright & Co. |
Aethlon Medical Inc. Press Releases
Fastest customizable press release news feed in the world
Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now
MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - TodayMarch 26, 2025 11:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to
Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now
MIAMI, March 25, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com. For updates, follow us on Twitter. Day 1March 26, 2025 11:00Virtual Lobby opens.Register for the Conference. If you already registered, go
Aethlon Medical Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal
Preclinical Data Suggests Expanded Therapeutic Potential of the Hemopurifier® Beyond Virology and Oncology Results Support Further Evaluation of the Hemopurifier® as Part of a Machine Perfusion Circuit to Further Assess its Impact on the Function of Retrieved Kidneys SAN DIEGO, March 10, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases and for use in organ transplantation, today announced the publication of a pre-clinical study in the peer-reviewed journal Transplant Immunology (https://doi.org/10.1016/j.trim.2025.102215) on February 28, 2025, entitled, " A lectin a
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 2 - TodayFebruary 19, 2025 Replay Day 1 here:https://emerginggrowt
Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now
MIAMI, Feb. 18, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1February 18, 2025 9:30Virtual Lobby opens.Register for the Conference. If you already registered, go back to the
Aethlon Medical to Present at the Emerging Growth Conference on February 19, 2025
Aethlon Medical invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. SAN DIEGO, Feb. 13, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 19, 2025. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with Aethlon Medical's Chief Executive Officer, Mr. James Frakes, in real time.
Aethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update
Key Milestone Achieved: First Patient treated in Hemopurifier® Safety, Feasibility, and Dose Finding Study for Solid Tumors Not Responding to Anti-PD-1 Antibodies Patient Enrollment Open at Two Australian for Hemopurifier® Cancer Trial Operating Expenses Significantly Reduced Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2024 and provided an update on recent developments. Company Updates During the third quarter, a
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025
SAN DIEGO, Feb. 5, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2024, at 4:15 p.m. ET on Wednesday, February 12, 2025. Management will host a conference call on Wednesday, February 12, 2024, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10196811/fe
Aethlon Medical Treats First Patient in Australian Hemopurifier® Cancer Trial
First Patient enrolled and treated at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon Advances Hemopurifier® Study in Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO, Jan. 29, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced a significant milestone: the treatment of the first patient with the Hemopurifier in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier. This trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 monothera
Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu
SAN DIEGO, Dec. 20, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided a statement of its investigational medical device with respect to H5N1 avian influenza "Bird Flu." Aethlon has recently received a number of inquiries regarding the potential utility of its Hemopurifier device in the treatment of Bird Flu. These inquiries come on the heels of the reporting of isolation of Bird Flu in dairy cows, 60 human cases in eight states including
Aethlon Medical Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
HC Wainwright & Co. reiterated coverage on Aethlon Medical with a new price target
HC Wainwright & Co. reiterated coverage of Aethlon Medical with a rating of Buy and set a new price target of $9.00 from $5.00 previously
HC Wainwright & Co. initiated coverage on Aethlon Medical with a new price target
HC Wainwright & Co. initiated coverage of Aethlon Medical with a rating of Buy and set a new price target of $5.00
Aethlon Medical Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
Director Broenniman Edward G covered exercise/tax liability with 1,645 shares, decreasing direct ownership by 4% to 38,884 units (SEC Form 4)
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
Director Shah Chetan covered exercise/tax liability with 3,289 shares, decreasing direct ownership by 9% to 31,376 units (SEC Form 4)
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
Director Gikakis Nicolas covered exercise/tax liability with 3,289 shares, decreasing direct ownership by 9% to 31,463 units (SEC Form 4)
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
Director Broenniman Edward G covered exercise/tax liability with 1,645 shares, decreasing direct ownership by 4% to 40,529 units (SEC Form 4)
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
Director Shah Chetan covered exercise/tax liability with 3,289 shares, decreasing direct ownership by 9% to 34,665 units (SEC Form 4)
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
Director Gikakis Nicolas covered exercise/tax liability with 3,289 shares, decreasing direct ownership by 9% to 34,752 units (SEC Form 4)
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
Director Shah Chetan covered exercise/tax liability with 3,289 shares, decreasing direct ownership by 8% to 37,954 units (SEC Form 4)
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
Director Broenniman Edward G covered exercise/tax liability with 1,645 shares, decreasing direct ownership by 4% to 42,174 units (SEC Form 4)
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
Director Gikakis Nicolas covered exercise/tax liability with 3,289 shares, decreasing direct ownership by 8% to 38,041 units (SEC Form 4)
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
Director Gikakis Nicolas covered exercise/tax liability with 5,244 shares, decreasing direct ownership by 11% to 41,330 units (SEC Form 4)
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
Aethlon Medical Inc. SEC Filings
Aethlon Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits
8-K - AETHLON MEDICAL INC (0000882291) (Filer)
SEC Form SCHEDULE 13G filed by Aethlon Medical Inc.
SCHEDULE 13G - AETHLON MEDICAL INC (0000882291) (Subject)
SEC Form 10-Q filed by Aethlon Medical Inc.
10-Q - AETHLON MEDICAL INC (0000882291) (Filer)
Aethlon Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - AETHLON MEDICAL INC (0000882291) (Filer)
Amendment: SEC Form 1-A/A filed by Aethlon Medical Inc.
1-A/A - AETHLON MEDICAL INC (0000882291) (Filer)
Aethlon Medical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K - AETHLON MEDICAL INC (0000882291) (Filer)
SEC Form 1-A filed by Aethlon Medical Inc.
1-A - AETHLON MEDICAL INC (0000882291) (Filer)
Aethlon Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - AETHLON MEDICAL INC (0000882291) (Filer)
SEC Form S-8 filed by Aethlon Medical Inc.
S-8 - AETHLON MEDICAL INC (0000882291) (Filer)
SEC Form 10-Q filed by Aethlon Medical Inc.
10-Q - AETHLON MEDICAL INC (0000882291) (Filer)
Aethlon Medical Inc. Financials
Live finance-specific insights
Aethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update
Key Milestone Achieved: First Patient treated in Hemopurifier® Safety, Feasibility, and Dose Finding Study for Solid Tumors Not Responding to Anti-PD-1 Antibodies Patient Enrollment Open at Two Australian for Hemopurifier® Cancer Trial Operating Expenses Significantly Reduced Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2024 and provided an update on recent developments. Company Updates During the third quarter, a
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025
SAN DIEGO, Feb. 5, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2024, at 4:15 p.m. ET on Wednesday, February 12, 2025. Management will host a conference call on Wednesday, February 12, 2024, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10196811/fe
Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update
Achieves Key Milestone with Enrollment of First Two Patients in the Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies Two Australian Sites Open For Patient Enrollment in Hemopurifier® Cancer Trial Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, Nov. 13, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2024 and provided an update on recent developments. Company Updates During the seco
Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update
Received Two Australian Ethics Committee Approvals for a Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies; Expects to Open Patient Enrollment in October of 2024 Achieved Significant 24% Reduction in Fiscal First Quarter Operating Expenses Compared to the Same Period in 2023 Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, Aug. 14, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal first quarter ended June 30, 2024 and p
Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 14, 2024
SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal first quarter ended June 30, 2024, at 4:15 p.m. ET on Wednesday, August 14, 2024. Management will host a conference call on Wednesday, August 14, 2024, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference by navigating to https://dpregister.com/sreg/10191735/fd44630e3d. Ple
Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update
Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, June 27, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal year ended March 31, 2024 and provided an update on recent developments. Company Updates Aethlon Medical is continuing the research and clinical development of its Hemopurifier®, a therapeutic blood filtration system designed to bind and remove harmful exosomes and life-threatening viruses from blood and other biological fluids. These qualities of the Hemopurifier have potential applications in oncolo
Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024
SAN DIEGO, June 21, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal year ended March 31, 2024, at 4:15 p.m. ET on Thursday, June 27, 2024. Management will host a conference call on Thursday, June 27, 2024, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference by navigating to https://dpregister.com/sreg/10190237/fce977aef1. Please note that
Blood Purification Medical Devices Revolutionizing the Future of Health from Cancer to COVID
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 3, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at medical device advancements for blood purification, featuring Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.Read the full article on Investorideas.comhttps://www.investorideas.com/News/2024/biotech/06030Blood-Purification-Medical-Devices.aspAccording to Straits Research, "The global blood purification equipment market size was valued at USD 17,755.6 million in 2021. It is expected to reach USD 29242.21 mill
Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update
Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2023 and provided an update on recent developments. Company Updates Aethlon Medical is continuing the research and clinical development of its Hemopurifier®, a therapeutic blood filtration system designed to bind and remove harmful exosomes and life-threatening viruses from blood and other biological fluids. These qualities of the Hemopurifier have potential applicatio
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024
SAN DIEGO, Feb. 7, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2023, at 4:15 p.m. ET on Wednesday, February 14, 2024. Management will host a conference call on Wednesday, February 14, 2023 at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference by navigating to https://dpregister.com/sreg/10186345/fb902976
Aethlon Medical Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
SEC Form SC 13G/A filed by Aethlon Medical, Inc. (Amendment)
SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)
SEC Form SC 13G filed by Aethlon Medical, Inc.
SC 13G - AETHLON MEDICAL INC (0000882291) (Subject)
SEC Form SC 13G/A filed
SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)